MIAMI (CBSMiami) — A single dose of the COVID-19 monoclonal antibody therapy REGEN-COV reduced the risk of contracting the virus by 81.6% for up to eight months, following the drug’s administration in a late-stage trial, according to results released by the Regeneron company on Monday.
Monoclonal antibodies are man-made proteins that act like human antibodies in the immune system to fight off harmful pathogens such as viruses. Four infusions of the Regeneron treatment are considered one dose.READ MORE: Seminoles Suspend Sports Betting After Court Rulings
“These results demonstrate that REGEN-COV has the potential to provide long-lasting immunity from SARS-CoV-2 infection, a result particularly important to those who do not respond to COVID-19 vaccines including people who are immunocompromised,” Dr. Myron Cohen, a physician in charge of the National Institutes of Health’s work on monoclonal antibodies, said in a news release.
A previously published study in the New England Journal of Medicine already showed its effectiveness but this is a new analysis of that data. It came from a trial assessing giving the treatment to one household member if another was sick to see if it could prevent testing positive for the virus.READ MORE: Sharp Increase In Hospitalized Children With Covid Investigated In South Africa
The results came from 1,684 people who participated in the Phase 3, randomized, placebo-controlled trial.
Regeneron said none of the participants who were injected with a single dose of the ‘REGEN-COV’ antibody cocktail were hospitalized with COVID-19 during the eight-month trial run, however, six people in the placebo group were hospitalized with COVID-19, according to the results.MORE NEWS: Police Shoot, Kill Knife-Wielding Suspect At Florida Institute of Technology
The FDA authorized REGEN-COV for emergency use as post-exposure prevention for COVID-19 a year ago, however, the FDA says REGEN-COV is not a substitute for vaccination against COVID-19 and still urges all eligible people to get vaccinated.